USFDA completes inspection at Divi's Laboratories’ Unit-II facility in Chippada

17 Jun 2019

US Food and Drug Administration (USFDA) has completed inspection at Divi's Laboratories’ Unit-II at village Chippada, Bheemunipatnam District in the state of Andhra Pradesh (AP). The inspection was conducted from June 10 to 15, 2019.

This was a general CGMP inspection by the US-FDA. The inspection has been concluded with no 483 observations.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Related Divis Laboratories Ltd. Links:

Divis Lab Share Price

3057.30 -35.60 (-1.15%) Sep 29, 16:43
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 505.60
Dr. Reddys Lab 5083.50
Lupin 995.00
Piramal Enterprises 1253.15
Cadila Healthcare 386.75
View more..
Sensex vs Divis Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback